COMING SOON
2.1 Cancer Glycobiology
2.2 Glyco-Immune Checkpoints
2.3 Limitations Of Current Immune Checkpoint Inhibitors
4.1 Anti-Glycan Antibodies
4.2 Glycan Editing Approaches
4.3 Lectin-Based Therapeutics
4.4 Glycan-Degrading Enzymes
4.5 Decoy Receptors
4.6 Positioning Of Antibody-Lectin Chimeras
5.1 Platform Overview
5.2 Molecular Design
5.3 Mechanism Of Action
5.4 Patent Landscape
5.5 Target Selection Strategy
5.6 Advantages Over Existing Modalities
5.7 Potential Challenges
6.1 Current Evidence and Development Status
6.2 Future Development Opportunities
7.1 Drivers and Opportunities
7.2 Challenges and Development Risks
8.1 Valora Therapeutics
8.1.1 Company Overview
8.1.2 Platform Technology
Figure 2-1: Cancer Glycobiology: From Normal Glycosylation To Malignant Transformation
Figure 2-2: Biological Consequences Of Aberrant Glycosylation
Figure 2-3: Major Cancer-Associated Glycan Alterations
Figure 2-4: Glycans Promote Cancer Progression
Figure 2-5: Cancer Glycobiology Leads To Glyco-Immunology
Figure 2-6: Impact Of Siglec Activation On Innate Immunity
Figure 2-7: Glyco-Immune Checkpoints Regulate Adaptive Immunity
Figure 2-8: Major Limitations Of Current Immune Checkpoint Inhibitors
Figure 2-9: Why Many Patients Do Not Respond To Immune Checkpoint Inhibitors
Figure 2-10: Mechanisms Of Primary and Acquired Resistance
Figure 2-11: Emergence Of Alternative Immune Checkpoints
Figure 2-12: Immune-Related Adverse Events Following Checkpoint Blockade
Figure 3-1: Why Glyco-Immune Checkpoints Matter In Cancer
Figure 3-2: Glyco-Immune Checkpoints Connect Multiple Hallmarks Of Cancer
Figure 4-1: Development Of Anti-Glycan Antibodies In Cancer Therapy
Figure 4-2: Clinical Success Of GD2-Targeted Therapy
Figure 4-3: Limitations Of Anti-Glycan Antibodies
Figure 4-4: Why Anti-Glycan Antibodies Are Not Sufficient
Figure 4-5: Major Glycan Editing Strategies
Figure 4-6: Challenges Of Glycan Editing
Figure 4-7: Mechanisms Of Lectin-Based Therapeutics
Figure 4-8: Challenges Of Lectin Based Therapeutics
Figure 4-9: Engineering Strategies For Lectin Therapeutics
Figure 4-10: Evolution Of Lectin-Based Therapeutics
Figure 4-11: Catalytic Advantage Of Glycan-Degrading Enzymes
Figure 4-12: Mechanism Of Glycan Degrading Enzymes
Figure 4-13: Biological Effects Of Desialylation
Figure 4-14: Challenges of Glycan-Degrading Enzyme Therapy
Figure 4-15: Siglec-Fc Decoy Receptor Structure
Figure 4-16: Therapeutic Actions Of Siglec Decoy Receptors
Figure 4-17: Decoy Receptors v/s Conventional Checkpoint Blockade
Figure 4-18: Limitations Of Soluble Decoy Receptors
Figure 4-19: Evolution Toward Antibody-Lectin Chimeras
Figure 4-20: Immunological Effects Of AbLecs
Figure 5-1: Therapeutic Workflow Of AbLec Platform
Figure 5-2: Position Of AbLecs Within The Cancer-Immunity Cycle
Figure 5-3: Engineering Strategy For Constructing An Antibody-Lectin Chimera
Figure 5-4: Affinity v/s Avidity In AbLec Design
Figure 5-5: Sequential Mechanism Of Action Of Antibody-Lectin Chimeras
Figure 5-6: Cellular Consequences Of Glyco-Immune Checkpoint Blockade
Figure 5-7: Workflow For Selecting An AbLec Therapeutic Target
Figure 5-8: Factors Influencing Target Selection
Figure 5-9: Key Advantages Of AbLecs Over Existing Glycan-Targeting Modalities
Figure 5-10: Major Scientific, Biological and Translational Challenges Associated With AbLec Development
Figure 6-1: Future Development Opportunities For AbLec Platform
Figure 7-1: Major Market Drivers Supporting Development and Commercialization Of AbLecs
Figure 7-2: Key Market Challenges Affecting Clinical Translation and Commercialization Of AbLecs
Figure 8-1: Antibody-Lectin Chimera - General Molecular Structure
List Of Tables
Table 2-1: Major Glyco Immune Checkpoint Pathways
Table 2-2: Major Limitations Of Current Immune Checkpoint Inhibitors
Table 4-1: Glycan Editing v/s Anti-Glycan Antibodies
Table 4-2: Major Glycan-Degrading Enzymes Relevant To Cancer Therapy
Table 4-3: Evolution Of Glycan-Targeting Therapeutics
Table 4-4: Comparison Of Major Glycan-Targeting Modalities
Table 5-1: Design Principles Of AbLec Platform
Table 5-2: Key Characteristics Of An Ideal AbLec Platform
Table 5-3: Therapeutic Objectives Of AbLec Platform
Table 5-4: Immune Cells Influenced By AbLec Therapy
Table 5-5: Key Features Of AbLec Patent Portfolio
Table 5-6: Examples Of Potential Antibody-Lectin Pairings
